Compatibility of aztreonam in four commercial peritoneal dialysis fluids.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 02 2020
04 02 2020
Historique:
received:
15
07
2019
accepted:
09
01
2020
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
18
11
2020
Statut:
epublish
Résumé
The preferable route for treatment of peritoneal dialysis related peritonitis remains the intraperitoneal administration of antibiotics admixed to peritoneal dialysis fluids. It is important to know whether the administered drug is compatible with the PD fluids and its container. In the present study the compatibility of aztreonam with four commercial PDFs at storing temperatures and duration representative for storing conditions in the clinical settings was investigated. Aztreonam concentrations were determined using high-performance liquid chromatography. The antimicrobial activity of aztreonam was evaluated using an E. coli diffusion disk inhibition assay and P. aeruginosa time-kill curves. In Extraneal evaluated at 6 °C, 25 °C and 37 °C aztreonam was stable over the whole study period of 14 days and 24 hours, respectively. In Physioneal and Nutrineal aztreonam was stable at 6 °C for up to 14 days. Antimicrobial activity was retained in all PD fluids over the whole study period. Aztreonam remained stable and was compatible with the PD fluids, particularly with Extraneal or Nutrineal, and no compensatory dose adjustment is needed when stored for up to 14 days at refrigeration temperature before use.
Identifiants
pubmed: 32019947
doi: 10.1038/s41598-020-58391-y
pii: 10.1038/s41598-020-58391-y
pmc: PMC7000415
doi:
Substances chimiques
Anti-Bacterial Agents
0
Dialysis Solutions
0
Aztreonam
G2B4VE5GH8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1788Références
Li, P. K. et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Perit. Dial. Int. 36, 481–508, https://doi.org/10.3747/pdi.2016.00078 (2016).
doi: 10.3747/pdi.2016.00078
pubmed: 27282851
pmcid: 5033625
Zelenitsky, S. A. et al. Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. Perit. Dial. Int. 37, 170–176, https://doi.org/10.3747/pdi.2016.00136 (2017).
doi: 10.3747/pdi.2016.00136
pubmed: 27738087
Bernardini, J., Piraino, B. & Sorkin, M. Analysis of continuous ambulatory peritoneal dialysis-related Pseudomonas aeruginosa infections. Am. J. Med. 83, 829–832, https://doi.org/10.1016/0002-9343(87)90638-3 (1987).
doi: 10.1016/0002-9343(87)90638-3
pubmed: 3674090
Siva, B. et al. Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. Clin. J. Am. Soc. Nephrol. 4, 957–964, https://doi.org/10.2215/CJN.00010109 (2009).
doi: 10.2215/CJN.00010109
pubmed: 19406972
pmcid: 2676190
Szeto, C. C. et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. Kidney Int. 59, 2309–2315, https://doi.org/10.1046/j.1523-1755.2001.00748.x (2001).
doi: 10.1046/j.1523-1755.2001.00748.x
pubmed: 11380835
Patolia, S., Abate, G., Patel, N. & Frey, S. Risk factors and outcomes for multidrug-resistant Gram-negative bacilli bacteremia. Ther. Adv. Infect. Dis. 5, 11–18, https://doi.org/10.1177/2049936117727497 (2018).
doi: 10.1177/2049936117727497
pubmed: 29344356
Cheng, I. K., Chan, C. Y. & Wong, W. T. A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 11, 27–30 (1991).
pubmed: 2049419
Gerig, J. S., Bolton, N. D., Swabb, E. A., Scheld, W. M. & Bolton, W. K. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int. 26, 308–318 (1984).
doi: 10.1038/ki.1984.174
Brown, J., Altmann, P., Cunningham, J., Shaw, E. & Marsh, F. Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis. J. Antimicrob. Chemother. 25, 141–147, https://doi.org/10.1093/jac/25.1.141 (1990).
doi: 10.1093/jac/25.1.141
pubmed: 2318749
Fuiano, G., Sepe, V., Viscione, M., Nani, E. & Conte, G. Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 9, 273–275 (1989).
pubmed: 2488380
de Vin, F., Rutherford, P. & Faict, D. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit. Dial. Int. 29, 5–15 (2009).
pubmed: 19164246
Kussmann, M. et al. Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. Sci. Rep. 9, 6512, https://doi.org/10.1038/s41598-019-42854-y (2019).
doi: 10.1038/s41598-019-42854-y
pubmed: 31019280
pmcid: 6482149
Kussmann, M. et al. Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. Eur. J. Clin. Microbiol. Infect. Dis. 36, 2237–2242, https://doi.org/10.1007/s10096-017-3051-3 (2017).
doi: 10.1007/s10096-017-3051-3
pubmed: 28685187
pmcid: 5653715
Tobudic, S. et al. Stability of anidulafungin in two standard peritoneal dialysis fluids. Perit. Dial. Int. 34, 798–802, https://doi.org/10.3747/pdi.2012.00326 (2014).
doi: 10.3747/pdi.2012.00326
pubmed: 25520485
pmcid: 4269507
Htay, H. et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst. Rev. 10, CD007554, https://doi.org/10.1002/14651858.CD007554.pub3 (2018).
doi: 10.1002/14651858.CD007554.pub3
pubmed: 30362116
Kussmann, M. et al. Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 37, 1091–1098, https://doi.org/10.1007/s10096-018-3221-y (2018).
doi: 10.1007/s10096-018-3221-y
pubmed: 29546637
pmcid: 5948293
Poeppl, W. et al. Compatibility of linezolid with commercial peritoneal dialysis solutions. Am. J. Health Syst. Pharm. 75, 1467–1477, https://doi.org/10.2146/ajhp170318 (2018).
doi: 10.2146/ajhp170318
pubmed: 30257843
Viaene, E., Chanteux, H., Servais, H., Mingeot-Leclercq, M. P. & Tulkens, P. M. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46, 2327–2332 (2002).
doi: 10.1128/AAC.46.8.2327-2332.2002
Dratwa, M. et al. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. Rev. Infect. Dis. 13(Suppl 7), S645–647 (1991).
doi: 10.1093/clinids/13.Supplement_7.S645
Nikolaidis, P., Dombros, N., Alexiou, P., Balaskas, E. & Tourkantonis, A. Pharmacokinetics of aztreonam administered i.p. in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit. Dial. Int. 9, 57–59 (1989).
pubmed: 2488183
Cho, Y. et al. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int. 84, 969–979, https://doi.org/10.1038/ki.2013.190 (2013).
doi: 10.1038/ki.2013.190
pubmed: 23698236
Wiesholzer, M. et al. Compatibility of Meropenem with Different Commercial Peritoneal Dialysis Solutions. Perit. Dial. Int. 37, 51–55, https://doi.org/10.3747/pdi.2016.00018 (2017).
doi: 10.3747/pdi.2016.00018
pubmed: 27605684
Manley, H. J. & Bailie, G. R. Treatment of peritonitis in APD: pharmacokinetic principles. Semin. Dial. 15, 418–421 (2002).
doi: 10.1046/j.1525-139X.2002.00103.x
Peyro Saint Paul, L. et al. Daptomycin compatibility in peritoneal dialysis solutions. Perit Dial Int 31, 492–495, https://doi.org/10.3747/pdi.2010.00183 (2011).
doi: 10.3747/pdi.2010.00183